Impaired_JJ Macrophage_NP Phagocytosis_NP of_IN Apoptotic_NP Neutrophils_NP in_IN Patients_NPS with_IN Human_NP Immunodeficiency_NN Virus_NP Type_NP 1_CD Infection_NN Dysfunction_NN of_IN neutrophils_NNS (_( polymorphonuclear_JJ leukocytes_NNS [_SYM PMNL_NP ]_SYM )_) and_CC macrophagic_JJ cells_NNS occurs_VBZ as_IN a_DT consequence_NN of_IN human_JJ immunodeficiency_NN virus_NN type_NN 1_CD (_( HIV-1_NP )_) infection_NN ._SENT Macrophages_NNS contribute_VBP to_TO the_DT resolution_NN of_IN early_JJ inflammation_NN ingesting_VBG PMNL_NP apoptotic_JJ bodies_NNS ._SENT This_DT study_NN investigated_VBD macrophage_NN ability_NN to_TO phagocytose_JJ PMNL_NP apoptotic_JJ bodies_NNS in_IN patients_NNS with_IN HIV-1_JJ infection_NN in_IN comparison_NN with_IN uninfected_JJ individuals_NNS and_CC the_DT effect_NN of_IN HIV_NP Nef_NP protein_NN on_IN apoptotic_JJ body_NN phagocytosis_NN to_TO determine_VB if_IN phagocytic_JJ activity_NN is_VBZ impaired_VBN by_IN HIV_NP infection_NN ._SENT Monocytes/macrophages_NNS were_VBD isolated_VBN from_IN 10_CD HIV-1-infected_JJ patients_NNS and_CC from_IN five_CD healthy_JJ volunteers_NNS ,_, whereas_IN PMNL_NP were_VBD isolated_VBN from_IN healthy_JJ volunteers_NNS ._SENT Macrophage_NN phagocytosis_NN of_IN apoptotic_JJ PMNL_NN was_VBD determined_VBN by_IN staining_VBG of_IN apoptotic_JJ bodies_NNS with_IN fluorescein-conjugated_JJ concanavalin_NP A_NP or_CC with_IN fluorescein-labeled_JJ phalloidin_NN ._SENT Our_PP$ data_NNS show_VBP significant_JJ impairment_NN of_IN PMNL_NP apoptotic_JJ body_NN macrophage_NN phagocytosis_NN in_IN subjects_NNS with_IN HIV-1_JJ infection_NN presenting_VBG a_DT concentration_NN of_IN CD4+_NP T_NN lymphocytes_NNS of_IN >200/mm3_NN and_CC in_IN particular_JJ in_IN those_DT with_IN <200_JJ CD4+_NP T_NN lymphocyte_NN cells/mm3_NN ._SENT In_IN addition_NN ,_, HIV-1_NP recombinant_JJ Nef_NP protein_NN is_VBZ able_JJ to_TO decrease_VB phagocytosis_NN of_IN apoptotic_JJ PMNL_NN from_IN normal_JJ human_JJ macrophages_NNS in_IN a_DT dose-dependent_JJ manner_NN ._SENT The_DT results_NNS of_IN our_PP$ study_NN suggest_VBP that_IN impaired_JJ macrophage_NN phagocytosis_NN of_IN PMNL_NP apoptotic_JJ bodies_NNS may_MD contribute_VB to_TO the_DT persistence_NN of_IN the_DT inflammatory_JJ state_NN in_IN HIV-infected_JJ subjects_NNS ,_, especially_RB during_IN opportunistic_JJ infections_NNS that_WDT are_VBP often_RB favored_VBN by_IN defective_JJ phagocytic_JJ activity_NN ._SENT Neutrophil_JJ (_( polymorphonuclear_JJ leukocytes_NNS [_SYM PMNL_NP ]_SYM )_) function_NN ,_, including_VBG chemotaxis_NN ,_, phagocytosis_NN ,_, oxidative_JJ burst_NN capacity_NN ,_, and_CC bacterial_JJ killing_NN ,_, is_VBZ impaired_VBN in_IN the_DT course_NN of_IN human_JJ immunodeficiency_NN virus_NN type_NN 1_CD (_( HIV-1_NP )_) infection_NN ,_, particularly_RB in_IN the_DT later_JJR stages_NNS of_IN the_DT disease_NN ,_, and_CC this_DT abnormal_JJ function_NN may_MD predispose_VB to_TO some_DT secondary_JJ bacterial_JJ infections_NNS and/or_CC to_TO opportunistic_JJ infections_NNS ._SENT PMNL_NNS have_VBP the_DT shortest_JJS half-life_NN of_IN all_DT circulating_VBG leukocytes_NNS and_CC are_VBP programmed_VBN to_TO die_VB within_IN 1_CD day_NN ._SENT These_DT aging_VBG leukocytes_NNS spontaneously_RB undergo_VBP apoptosis_NN and_CC are_VBP recognized_VBN and_CC phagocytosed_VBN by_IN macrophages_NNS ._SENT Pitrak_NP et_FW al._FW have_VBP demonstrated_VBN that_IN the_DT rate_NN of_IN PMNL_NP apoptosis_NN is_VBZ accelerated_VBN in_IN AIDS_NP patients_NNS ,_, and_CC this_DT defect_NN is_VBZ intrinsic_JJ and_CC not_RB an_DT effect_NN of_IN endogenous_JJ serum_NN factors_NNS ._SENT Moreover_RB ,_, it_PP has_VBZ been_VBN proposed_VBN that_IN the_DT ingestion_NN of_IN apoptotic_JJ PMNL_NN triggers_VBZ production_NN of_IN anti-inflammatory_JJ mediators_NNS from_IN macrophages_NNS ,_, whereas_IN persistent_JJ PMNL-rich_NP inflammatory_JJ infiltrates_NNS have_VBP been_VBN associated_VBN with_IN unresolved_JJ inflammatory_JJ reactions_NNS ,_, including_VBG adult_JJ respiratory_JJ distress_NN syndrome_NN and_CC rheumatoid_JJ arthritis_NN ._SENT Thus_RB ,_, the_DT removal_NN of_IN apoptotic_JJ cells_NNS appears_VBZ to_TO be_VB critical_JJ in_IN the_DT resolution_NN of_IN inflammation_NN ._SENT We_PP have_VBP previously_RB demonstrated_VBN that_IN macrophages_NNS from_IN HIV-positive_JJ subjects_NNS have_VBP a_DT reduced_VBN ability_NN to_TO phagocytose_JJ Candida_NP albicans_NNS cells_NNS ,_, and_CC there_EX is_VBZ a_DT significant_JJ decrease_NN in_IN oxidative_JJ processes_NNS for_IN the_DT intracellular_JJ killing_NN ._SENT These_DT phenomena_NNS seem_VBP to_TO be_VB induced_VBN ,_, at_IN least_JJS in_IN part_NN ,_, by_IN HIV_NP Nef_NP protein_NN ._SENT Since_IN the_DT effects_NNS of_IN macrophage_NN phagocytosis_NN of_IN apoptotic_JJ PMNL_NP have_VBP not_RB been_VBN completely_RB investigated_VBN ,_, especially_RB in_IN HIV-positive_JJ subjects_NNS ,_, the_DT purpose_NN of_IN this_DT study_NN was_VBD to_TO evaluate_VB phagocytosis_NN of_IN PMNL_NP apoptotic_JJ bodies_NNS performed_VBN by_IN macrophagic_JJ cells_NNS obtained_VBN from_IN HIV-1-positive_JJ subjects_NNS and_CC in_IN parallel_NN by_IN the_DT macrophages_NNS obtained_VBN from_IN healthy_JJ individuals_NNS ._SENT Furthermore_RB ,_, we_PP studied_VBD the_DT effect_NN of_IN Nef_NP protein_NN on_IN PMNL_NP apoptotic_JJ body_NN macrophagic_JJ phagocytosis_NN ,_, since_IN this_DT viral_JJ protein_NN is_VBZ able_JJ to_TO depress_VB both_DT specific_JJ and_CC nonspecific_JJ immune_JJ responses_NNS in_IN HIV-infected_JJ patients_NNS ,_, particularly_RB microbial_JJ phagocytosis_NN ._SENT Subjects_NNS ._SENT |_SYM Ten_CD HIV-1-infected_JJ subjects_NNS (_( mean_JJ age_NN ,_, 35.3_CD +-_NN 5.8_CD years_NNS )_) were_VBD enrolled_VBN and_CC five_CD healthy_JJ volunteers_NNS (_( mean_JJ age_NN ,_, 37.1_CD +-_NN 4.4_CD years_NNS )_) ,_, without_IN HIV-1_JJ risk_NN factors_NNS ,_, served_VBN as_IN controls_NNS ._SENT Five_CD of_IN the_DT HIV-1-infected_NP subjects_NNS presented_VBD more_JJR than_IN 200_CD CD4+_NP T_NN lymphocytes/mm3_NN (_( mean_NN =_SYM 517_CD +-_NN 225_CD )_) ,_, had_VBD a_DT CD4/CD8_NP T-cell_NN ratio_NN of_IN 0.5_CD +-_NN 0.1_CD ,_, and_CC had_VBD mean_JJ HIV-1_NP RNA_NP levels_NNS in_IN plasma_NN of_IN 32,628_CD +-_NN 42,188_CD copies/ml_NN ._SENT Five_CD patients_NNS had_VBD less_JJR than_IN 200_CD CD4+_NP T_NN lymphocytes/mm3_NN (_( mean_NN =_SYM 101_CD +-_NN 70_CD )_) ,_, a_DT ratio_NN of_IN 0.2_CD +-_NN 0.2_CD ,_, and_CC mean_VB HIV-1_NP RNA_NP levels_NNS of_IN 375,000_CD +-_NN 246,815/ml_JJ ._SENT All_PDT these_DT patients_NNS had_VBD a_DT moderate_JJ anemic_JJ state_NN and_CC were_VBD generally_RB studied_VBN before_IN receiving_VBG antiretroviral_JJ therapy_NN ._SENT In_IN fact_NN ,_, a_DT significant_JJ part_NN of_IN our_PP$ study_NN population_NN included_VBD individuals_NNS who_WP had_VBD ignored_VBN their_PP$ seropositive_JJ condition_NN for_IN a_DT long_JJ time_NN and_CC in_IN consequence_NN came_VBD to_TO medical_JJ evaluation_NN late_RB ._SENT Monocyte_NN and_CC PMNL_NN isolation_NN and_CC apoptotic_JJ body_NN preparation_NN ._SENT |_SYM Monocytes_NP obtained_VBN from_IN peripheral_JJ blood_NN of_IN healthy_JJ subjects_NNS and_CC HIV-1-infected_JJ patients_NNS were_VBD selected_VBN as_IN adhering_VBG cells_NNS after_IN separation_NN of_IN peripheral_JJ blood_NN mononuclear_JJ cells_NNS with_IN a_DT Ficoll_NP Paque_NP gradient_NN (_( Pharmacia_NP ,_, Uppsala_NP ,_, Sweden_NP )_) ._SENT After_IN repeated_VBN washes_VBZ ,_, the_DT adherent_JJ cells_NNS were_VBD harvested_VBN by_IN trypsinization_NN and_CC resuspended_JJ at_IN a_DT concentration_NN of_IN 106/ml_NP in_IN RPMI-1640_NP medium_NN (_( Gibco_NP ,_, Paisley_NP ,_, Scotland_NP )_) ,_, supplemented_VBN with_IN 10_CD %_NN fetal_JJ calf_NN serum_NN (_( Celbio_NP ,_, Milan_NP ,_, Italy_NP )_) ._SENT Then_RB ,_, macrophage_NN colony-stimulating_NN factor_NN (_( 10_CD ng/ml_NNS ;_: Genzyme_NP ,_, Milan_NP ,_, Italy_NP )_) was_VBD added_VBN to_TO the_DT medium_NN in_IN order_NN to_TO differentiate_VB monocytic_JJ cells_NNS into_IN activated_VBN macrophages_NNS ,_, and_CC the_DT cultures_NNS were_VBD maintained_VBN at_IN 37C_JJ with_IN 5_CD %_NN CO2_NN ._SENT Cellular_JJ cultures_NNS were_VBD enriched_VBN for_IN macrophages_NNS by_IN adherence_NN and_CC repeated_JJ trypsinization_NN and_CC ,_, to_TO obtain_VB a_DT pure_JJ population_NN ,_, by_IN phenotypic_JJ evaluation_NN (_( more_JJR than_IN 98_CD %_NN of_IN cells_NNS )_) ._SENT After_IN 7_CD days_NNS of_IN incubation_NN in_IN flasks_NNS (_( 25_CD cm2_NN ;_: Nunc_NP Kamstrup_NP ,_, Baltimore_NP ,_, Md._NP )_) ,_, the_DT cells_NNS were_VBD harvested_VBN by_IN trypsin_NN treatment_NN and_CC transferred_VBN ,_, at_IN a_DT final_JJ concentration_NN of_IN 5_CD x_NN 105/ml_NN ,_, to_TO four-well_NP chamber_NN slides_NNS (_( Lab-Tek_NP ;_: Nunc_NP )_) ._SENT Cultures_NNS of_IN PMNL_NP were_VBD obtained_VBN from_IN peripheral_JJ blood_NN of_IN healthy_JJ subjects_NNS by_IN separation_NN with_IN a_DT Polymorphoprep_JJ gradient_NN (_( Pharmacia_NP )_) ._SENT PMNL_NN cells_NNS spontaneously_RB go_VBP to_TO apoptosis_NN after_IN 24_CD h_NN of_IN culture_NN ,_, and_CC this_DT method_NN was_VBD adopted_VBN to_TO induce_VB apoptosis_NN ._SENT In_IN order_NN to_TO separate_VB the_DT apoptotic_JJ bodies_NNS of_IN PMNL_NP ,_, after_IN centrifugation_NN at_IN 600_CD rpm_NN for_IN 10_CD min_NN (_( to_TO remove_VB nonapoptotic_JJ cells_NNS )_) ,_, the_DT supernatants_NNS were_VBD centrifuged_VBN at_IN 3,000_CD rpm_NN ,_, and_CC the_DT pellets_NNS containing_VBG PMNL_NP apoptotic_JJ bodies_NNS were_VBD resuspended_VBN at_IN the_DT indicated_JJ concentrations_NNS ._SENT Fluorescent_JJ microscopy_NN for_IN phagocytosis_NN detection_NN ._SENT |_SYM Two_NP staining_VBG methods_NNS were_VBD used_VBN to_TO detect_VB apoptotic_JJ bodies_NNS of_IN PMNL_NP in_IN macrophagic_JJ cells_NNS ._SENT In_IN the_DT first_JJ method_NN ,_, 5_CD x_SYM 106_CD apoptotic_JJ bodies/ml_NN were_VBD incubated_VBN for_IN 20_CD min_NN at_IN room_NN temperature_NN with_IN fluorescein-conjugated_JJ concanavalin_NP A_NP (_( ConA_NP ;_: Calbiochem_NP Corp._NP ,_, La_NP Jolla_NP ,_, Calif._NP )_) at_IN a_DT final_JJ concentration_NN of_IN 150_CD mug/ml_NN ._SENT Then_RB the_DT apoptotic_JJ bodies_NNS were_VBD washed_VBN twice_RB by_IN centrifugation_NN for_IN 10_CD min_NN at_IN 3,000_CD rpm_NN and_CC resuspended_JJ in_IN RPMI-1640_NP with_IN 10_CD %_NN fetal_JJ calf_NN serum_NN at_IN a_DT concentration_NN of_IN 5_CD x_SYM 106/ml_JJ to_TO obtain_VB a_DT ratio_NN of_IN 5:1_CD per_IN macrophagic_JJ cell_NN (_( this_DT preparation_NN was_VBD diluted_VBN 1:2_CD in_IN the_DT wells_NNS containing_VBG macrophagic_JJ cells_NNS )_) ._SENT This_DT method_NN allows_VBZ uniform_JJ staining_VBG of_IN the_DT apoptotic_JJ body_NN surface_NN ,_, making_VBG the_DT apoptotic_JJ bodies_NNS easily_RB detectable_JJ in_IN macrophagic_JJ cells_NNS without_IN having_VBG any_DT significant_JJ influence_NN on_IN phagocytosing_NN activity_NN ._SENT In_IN the_DT second_JJ method_NN ,_, fluorescein-labeled_JJ phalloidin_NN (_( Sigma-Aldrich_NP Chemicals_NP ,_, Milan_NP ,_, Italy_NP )_) was_VBD used_VBN at_IN a_DT final_JJ concentration_NN of_IN 5_CD mug/ml_NN ._SENT This_DT product_NN is_VBZ able_JJ to_TO stain_VB the_DT interior_NN of_IN the_DT apoptotic_JJ bodies_NNS ,_, binding_VBG firmly_RB to_TO the_DT microtubular_JJ structures_NNS ._SENT This_DT staining_VBG method_NN was_VBD used_VBN like_IN the_DT first_JJ one_CD ._SENT In_IN a_DT subsequent_JJ set_NN of_IN experiments_NNS ,_, macrophage_NN phagocytosis_NN of_IN PMNL_NP apoptotic_JJ bodies_NNS was_VBD also_RB investigated_VBN in_IN the_DT presence_NN of_IN various_JJ concentrations_NNS of_IN recombinant_JJ Nef_NP protein_NN (_( American_NP Biotechnologies_NP ,_, Inc._NP ,_, Cambridge_NP ,_, Mass._NP )_) ,_, using_VBG macrophagic_JJ cells_NNS obtained_VBN from_IN four_CD healthy_JJ individuals_NNS and_CC performing_VBG the_DT experiments_NNS in_IN triplicate_NN ._SENT The_DT challenge_NN with_IN stained_VBN apoptotic_JJ bodies_NNS ,_, using_VBG both_CC the_DT first_JJ and_CC second_JJ methods_NNS ,_, was_VBD made_VBN at_IN a_DT ratio_NN of_IN 5:1_CD ._SENT After_IN 2_CD h_NN of_IN incubation_NN in_IN the_DT presence_NN of_IN apoptotic_JJ bodies_NNS ,_, the_DT supernatants_NNS were_VBD removed_VBN ,_, and_CC slides_NNS were_VBD detached_VBN from_IN their_PP$ supports_NNS and_CC washed_VBN twice_RB with_IN phosphate-buffered_JJ saline_NN (_( PBS_NP )_) ._SENT Then_RB the_DT slides_NNS were_VBD fixed_VBN with_IN 10_CD %_NN ethyl_NN alcohol_NN solution_NN ,_, mounted_VBN in_IN phosphate-buffered_JJ glycerol_NN (_( 30_CD %_NN PBS_NP and_CC 70_CD %_NN glycerol_NN ,_, vol/vol_NP )_) ,_, and_CC examined_VBD under_IN a_DT fluorescence_NN microscope_NN at_IN x400_NN by_IN four_CD blinded_VBN microscopists_NNS ._SENT At_IN least_JJS five_CD microscopic_JJ fields_NNS were_VBD observed_VBN for_IN each_DT sample_NN ._SENT Macrophage_NN oxidative_JJ phenomenon_NN evaluation_NN ._SENT |_SYM We_PP indirectly_RB studied_VBD the_DT oxidative_JJ phenomena_NNS of_IN macrophages_NNS in_IN the_DT absence_NN or_CC presence_NN of_IN Nef_NP protein_NN ,_, by_IN evaluating_VBG the_DT antioxidant_NN power_NN of_IN the_DT supernatants_NNS ,_, as_RB previously_RB described_VBN ._SENT For_IN this_DT purpose_NN we_PP used_VBD the_DT antioxidant_NN power_NN (_( PAO_NP )_) kit_NN furnished_VBN by_IN Med_NP ._SENT Dia_NP S.r.l._NP (_( San_NP Germano_NP ,_, Vercelli_NP ,_, Italy_NP )_) ._SENT The_DT test_NN is_VBZ based_VBN on_IN the_DT detection_NN of_IN Cu+_NP ions_NNS produced_VBN by_IN the_DT reduction_NN of_IN a_DT known_VBN amount_NN of_IN Cu2+_NP ;_: this_DT reduction_NN is_VBZ induced_VBN by_IN the_DT antioxidant_NN factors_NNS present_JJ in_IN the_DT culture_NN ,_, the_DT activity_NN of_IN which_WDT decreases_NNS in_IN an_DT inversely_RB proportional_JJ manner_NN to_TO the_DT activity_NN of_IN macrophage_NN oxidative_JJ phenomena_NNS ._SENT The_DT concentration_NN of_IN Cu2+_NP ion_NN was_VBD detected_VBN through_IN the_DT formation_NN of_IN complexes_NNS consisting_VBG of_IN Cu+_NP and_CC the_DT chelating_VBG agent_NN betacuproine_NN disulfonate_NN (_( 2,9-dimethyl-4,7-diphenyl-1,10-phenanthrolinedisulfonate_JJ )_) ,_, and_CC it_PP was_VBD measured_VBN spectrophotometrically_RB at_IN 490_CD nm_NN (_( Metertech_NP spectrophotometer_NN ;_: Medical_NP System_NP ,_, Genoa_NP ,_, Italy_NP )_) ._SENT The_DT data_NNS are_VBP expressed_VBN as_IN microequivalents_NNS per_IN liter_NN of_IN reducing_VBG equivalents_NNS +-_NN standard_NN deviation_NN ,_, corresponding_VBG to_TO PAO_NP units_NNS ._SENT Statistical_JJ analysis_NN ._SENT |_SYM The_DT results_NNS were_VBD expressed_VBN as_IN mean_JJ and_CC standard_JJ deviation_NN ._SENT The_DT differences_NNS among_IN the_DT experimental_JJ and_CC control_NN groups_NNS were_VBD statistically_RB evaluated_VBN using_VBG Student_NP 's_POS t_NN test_NN ._SENT Statistical_JJ significance_NN was_VBD defined_VBN as_IN P_NN <=_NP 0.05_CD ._SENT Moreover_RB ,_, a_DT linear_JJ correlation_NN test_NN was_VBD employed_VBN for_IN the_DT correlation_NN study_NN reported_VBD in_IN the_DT results_NNS ._SENT In_IN the_DT first_JJ set_NN of_IN experiments_NNS ,_, we_PP studied_VBD the_DT phagocytosis_NN of_IN PMNL_NP apoptotic_JJ bodies_NNS stained_VBN with_IN fluoresceinated_JJ ConA_NP from_IN macrophages_NNS of_IN patients_NNS with_IN HIV-1_JJ infection_NN and_CC from_IN those_DT of_IN uninfected_JJ healthy_JJ individuals_NNS ._SENT A_DT significant_JJ decrease_NN in_IN the_DT percentage_NN of_IN phagocytosing_NN cells_NNS was_VBD observed_VBN in_IN HIV-1-positive_JJ subjects_NNS presenting_VBG a_DT CD4+_NP T-cell_NN concentration_NN of_IN >200_JJ cells/mm3_NN (_( 24.2_CD %_NN +-_NN 12.3_CD %_NN ;_: P_NN =_SYM 0.002_CD )_) and_CC in_IN those_DT with_IN <200_JJ CD4+_NP T_NN cells/mm3_NN (_( 23.7_CD %_NN +-_NN 6.9_CD %_NN ;_: P_NN <_SYM 0.001_CD )_) ,_, compared_VBN to_TO healthy_JJ control_NN subjects_NNS (_( 50.1_CD %_NN +-_NN 3.7_CD %_NN )_) ._SENT We_PP point_VBP out_RP that_IN by_IN analyzing_VBG all_PDT the_DT HIV-positive_JJ subjects_NNS ,_, the_DT mean_JJ number_NN of_IN phagocytosing_NN cells_NNS was_VBD 23.9_CD %_NN +-_NN 10_CD %_NN in_IN 52_CD %_NN of_IN the_DT controls_NNS (_( P_NN <_0.001). 200_CD CD4_NP T_NN cells/mm3_NN (_( 0.6_CD +-_NN 0.4_CD ;_: P_NN =_SYM 0.001_CD )_) and_CC in_IN those_DT with_IN <200_JJ CD4_NP T_NN cells/mm3_NN (_( 0.3_CD +-_NN 0.1_CD ;_: P_NN <_SYM 0.001_LS )_) compared_VBN to_TO the_DT controls_NNS (_( 2.4_CD +-_NN 0.7_CD )_) ._SENT Evaluating_VBG all_PDT the_DT HIV-positive_JJ subjects_NNS ,_, the_DT mean_JJ number_NN of_IN apoptotic_JJ bodies_NNS phagocytosed_JJ per_IN cell_NN was_VBD 0.45_CD +-_NN 0.3_CD (_( P_NN <_SYM 0.001_CD )_) ._SENT As_RB can_MD be_VB seen_VBN in_IN Table_NP ,_, the_DT reduction_NN of_IN the_DT mean_JJ number_NN of_IN PMNL_NP apoptotic_JJ bodies_NNS phagocytosed_JJ per_IN cell_NN in_IN HIV-positive_JJ subjects_NNS compared_VBN to_TO the_DT controls_NNS is_VBZ fivefold_JJ ,_, and_CC the_DT percent_NN reduction_NN in_IN phagocytosing_VBG cells_NNS in_IN infected_JJ patients_NNS is_VBZ twofold_JJ ._SENT This_DT observation_NN suggests_VBZ a_DT decreased_VBN ability_NN of_IN single_JJ phagocytosing_NN cells_NNS to_TO swallow_VB apoptotic_JJ bodies_NNS ._SENT In_IN a_DT further_JJR set_NN of_IN experiments_NNS ,_, we_PP studied_VBD the_DT phagocytic_JJ activity_NN of_IN PMNL_NP apoptotic_JJ bodies_NNS in_IN normal_JJ human_JJ macrophages_NNS preincubated_VBN with_IN recombinant_JJ Nef_NP protein_NN ._SENT The_DT results_NNS obtained_VBN demonstrate_VBP that_IN this_DT protein_NN is_VBZ able_JJ to_TO inhibit_VB the_DT phagocytosis_NN of_IN PMNL_NP apoptotic_JJ bodies_NNS ._SENT In_IN particular_JJ ,_, preincubation_NN with_IN Nef_NP (_( 2_CD h_NN before_IN the_DT challenge_NN with_IN apoptotic_JJ bodies_NNS )_) inhibited_VBD macrophage_NN phagocytosis_NN of_IN PMNL_NP apoptotic_JJ bodies_NNS by_IN about_RB 50_CD %_NN (_( P_NN =_SYM 0.01_CD )_) at_IN the_DT concentration_NN of_IN 1_CD mug/ml_NN and_CC 65_CD %_NN at_IN the_DT concentration_NN of_IN 2_CD mug/ml_NN (_( P_NN <_SYM 0.001_CD )_) ._SENT When_WRB the_DT preincubation_NN time_NN was_VBD prolonged_JJ to_TO overnight_JJ ,_, inhibition_NN of_IN macrophage_NN phagocytosis_NN was_VBD 80_CD %_NN at_IN a_DT Nef_NP protein_NN concentration_NN of_IN 2_CD mug/ml_NN ._SENT Table_NN reports_VBZ the_DT mean_JJ number_NN of_IN PMNL_NP apoptotic_JJ bodies_NNS stained_VBN with_IN fluoresceinated_JJ phalloidin_NN phagocytosed_VBN per_IN cell_NN in_IN the_DT absence_NN or_CC presence_NN of_IN Nef_NP protein_NN ._SENT As_IN shown_VBN ,_, the_DT reduction_NN was_VBD about_RB 34_CD %_NN ,_, 90_CD %_NN ,_, and_CC 92_CD %_NN with_IN Nef_NP at_IN 0.5_CD ,_, 1_CD ,_, and_CC 2_CD mug/ml_NN ,_, respectively_RB ._SENT Consequently_RB ,_, in_IN these_DT experiments_NNS the_DT reductions_NNS induced_VBN by_IN Nef_NP were_VBD also_RB more_RBR evident_JJ when_WRB evaluating_VBG the_DT number_NN of_IN PMNL_NP apoptotic_JJ bodies_NNS phagocytosed_JJ per_IN cell_NN than_IN the_DT percentage_NN of_IN phagocytosing_NN cells_NNS ._SENT Moreover_RB ,_, we_PP observed_VBD a_DT negative_JJ and_CC significant_JJ correlation_NN between_IN the_DT Nef_NP protein_NN concentration_NN and_CC the_DT number_NN of_IN PMNL_NP apoptotic_JJ bodies_NNS phagocytosed_JJ per_IN cell_NN (_( r_LS =_SYM -0.65_CD ;_: P_NN =_SYM 0.0221_CD )_) ._SENT The_DT mean_JJ number_NN of_IN apoptotic_JJ bodies_NNS phagocytosed_VBD related_VBN to_TO 106_CD macrophages_NNS was_VBD 1.18_CD x_SYM 106_CD in_IN the_DT absence_NN of_IN HIV_NP infection_NN (_( 23_CD %_NN of_IN the_DT total_NN )_) and_CC 48,000_CD with_IN a_DT viral_JJ load_NN in_IN plasma_NN of_IN 8_CD x_SYM 105_CD HIV-1_NP RNA_NP copies/ml_NN (_( about_RB 1_CD %_NN )_) ._SENT A_DT negative_JJ correlation_NN was_VBD found_VBN between_IN the_DT HIV_NP RNA_NP load_NN and_CC the_DT number_NN of_IN apoptotic_JJ bodies_NNS phagocytosed_VBN (_( r_LS =_SYM -0.623_CD ;_: P_NN <_SYM 0.05_CD )_) ._SENT Finally_RB ,_, we_PP evaluated_VBD the_DT antioxidant_NN power_NN (_( PAO_NP )_) of_IN the_DT macrophage_NN supernatants_NNS in_IN the_DT absence_NN or_CC presence_NN of_IN various_JJ concentrations_NNS of_IN Nef_NP ,_, and_CC we_PP found_VBD a_DT significant_JJ increase_NN in_IN PAO_NP that_WDT meant_VBD a_DT reduction_NN of_IN oxidative_JJ phenomena_NNS in_IN the_DT presence_NN of_IN the_DT viral_JJ protein_NN compared_VBN to_TO the_DT control_NN values_NNS ,_, especially_RB at_IN a_DT concentration_NN of_IN 2_CD mug/ml_NN (_( PAO_NP units_NNS =_SYM 164.1_CD +-_NN 8.0_CD with_IN Nef_NP at_IN 2_CD mug/ml_NN versus_IN 105.6_CD +-_NN 12.9_CD without_IN Nef_NP ;_: P_NN <_SYM 0.001_CD )_) ._SENT TABLE_NN 1_CD |_SYM Percentage_NN of_IN macrophages_NNS phagocytosing_VBG PMNL_NP apoptotic_JJ bodies_NNS stained_VBN with_IN fluoresceinated_JJ ConA_NP :_: ex_JJ vivo_JJ test_NN of_IN macrophages_NNS from_IN uninfected_JJ and_CC HIV-1-infected_JJ subjects_NNS TABLE_NP 2_CD |_SYM Number_NP of_IN PMNL_NP apoptotic_JJ bodies_NNS phagocytosed_JJ per_IN macrophage_NN TABLE_NP 3_CD |_SYM Effect_NN of_IN Nef_NP viral_JJ protein_NN on_IN phagocytosis_NN of_IN PMNL_NP apoptotic_JJ bodies_NNS The_DT results_NNS of_IN this_DT study_NN show_VBP that_DT phagocytosis_NN of_IN PMNL_NP apoptotic_JJ bodies_NNS by_IN macrophages_NNS of_IN HIV-1-infected_JJ patients_NNS is_VBZ impaired_VBN and_CC that_IN Nef_NP ,_, a_DT regulatory_JJ viral_JJ protein_NN of_IN HIV_NP ,_, is_VBZ able_JJ to_TO decrease_VB phagocytosis_NN of_IN PMNL_NP apoptotic_JJ bodies_NNS by_IN human_JJ normal_JJ macrophages_NNS ._SENT In_IN addition_NN ,_, macrophagic_JJ oxidative_JJ phenomena_NNS are_VBP depressed_VBN by_IN Nef_NP protein_NN ._SENT This_DT is_VBZ relevant_JJ because_IN these_DT effects_NNS are_VBP involved_VBN in_IN intracellular_JJ killing_NN processes_NNS and_CC consequently_RB in_IN the_DT destruction_NN of_IN phagocytosed_JJ particles_NNS ._SENT The_DT decrease_NN in_IN oxidative_JJ processes_NNS and_CC the_DT inhibition_NN of_IN macrophagic_JJ function_NN seem_VBP to_TO occur_VB in_IN parallel_NN ._SENT Aging_VBG PMNL_NP spontaneously_RB undergo_VBP apoptosis_NN and_CC are_VBP recognized_VBN and_CC phagocytosed_VBN by_IN monocytes_NNS and_CC macrophages_NNS ._SENT PMNL_NN function_NN is_VBZ impaired_VBN in_IN all_DT stages_NNS of_IN HIV-1_JJ infection_NN and_CC especially_RB in_IN the_DT terminal_JJ stage_NN of_IN the_DT disease_NN ._SENT Pitrak_NP et_FW al._FW have_VBP shown_VBN that_IN abnormalities_NNS of_IN PMNL_NP function_NN observed_VBD in_IN HIV-positive_JJ subjects_NNS might_MD partly_RB depend_VB on_IN the_DT accelerated_VBN apoptosis_NN induced_VBN by_IN HIV_NP infection_NN ._SENT In_IN fact_NN ,_, during_IN all_DT stages_NNS of_IN HIV-1_JJ infection_NN ,_, there_EX is_VBZ an_DT increased_VBN number_NN of_IN apoptotic_JJ PMNL_NP which_WDT are_VBP unable_JJ to_TO function_VB as_IN host_NN defenders_NNS ._SENT The_DT removal_NN of_IN apoptotic_JJ cells_NNS appears_VBZ to_TO be_VB central_JJ to_TO the_DT resolution_NN of_IN inflammation_NN ._SENT In_IN fact_NN ,_, the_DT clearance_NN of_IN apoptotic_JJ PMNL_NN not_RB only_RB prevents_VBZ the_DT release_NN of_IN toxic_JJ and_CC immunogenic_JJ intracellular_JJ contents_NNS ,_, but_CC also_RB stimulates_VBZ the_DT macrophages_NNS to_TO produce_VB inflammatory_JJ mediators_NNS ,_, including_VBG transforming_VBG growth_NN factor_NN beta1_NN ,_, prostaglandin_NN E2_NN ,_, and_CC platelet-activating_VBG factor_NN ,_, and_CC inhibits_VBZ the_DT production_NN of_IN tumor_NN necrosis_NN factor_NN ,_, interleukin-1beta_NN ,_, and_CC interleukin-8_NN ._SENT Dysregulation_NN of_IN PMNL_NP function_NN ,_, along_RB with_IN that_IN of_IN monocytic_JJ macrophagic_JJ cells_NNS ,_, in_IN HIV-1-infected_JJ patients_NNS is_VBZ reflected_VBN in_IN the_DT increased_VBN incidence_NN of_IN some_DT microbial_JJ infections_NNS among_IN these_DT patients_NNS ._SENT During_IN several_JJ microbial_JJ infections_NNS ,_, PMNL_NP migrate_VBP and_CC accumulate_VBP at_IN the_DT inflammatory_JJ sites_NNS ,_, followed_VBN by_IN removal_NN of_IN inflammatory_JJ cells_NNS ._SENT This_DT occurs_VBZ mainly_RB by_IN apoptosis_NN and_CC by_IN phagocytosis_NN of_IN apoptotic_JJ bodies_NNS ._SENT In_IN parallel_NN ,_, some_DT antimicrobial_JJ pathogens_NNS can_MD be_VB phagocytosed_VBN and_CC killed_VBN by_IN macrophages_NNS ._SENT These_DT phenomena_NNS appears_VBZ to_TO be_VB critical_JJ to_TO the_DT resolution_NN of_IN inflammation_NN and_CC infection_NN ._SENT However_RB ,_, the_DT decreased_VBN phagocytosis_NN of_IN apoptotic_JJ PMNL_NN by_IN macrophages_NNS in_IN HIV-1-infected_JJ patients_NNS and_CC the_DT accelerated_VBN apoptosis_NN of_IN PMNL_NP lead_NN to_TO accumulation_NN of_IN apoptotic_JJ inflammatory_JJ PMNL_NN and_CC a_DT decrease_NN in_IN their_PP$ clearance_NN ._SENT The_DT persistence_NN of_IN apoptotic_JJ PMNL_NP and_CC their_PP$ apoptotic_JJ bodies_NNS at_IN the_DT inflammatory_JJ site_NN may_MD maintain_VB the_DT inflammatory_JJ state_NN through_IN persistent_JJ stimulation_NN of_IN proinflammatory_JJ cytokines_NNS ._SENT This_DT can_MD explain_VB some_DT of_IN the_DT pathological_JJ conditions_NNS in_IN the_DT gastrointestinal_JJ tract_NN or_CC bronchoalveolar_NN tract_NN that_WDT have_VBP been_VBN reported_VBN ._SENT 